Evidence map›Paper›PMID 41495001›Full record

ArticleThe oncologist2026

Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.

Bin Zhou, Zihui Ma, Lei Wang, Yue Lu, Xi Cheng, Yabo Jiang, Xubiao Wei, Chongde Lu, Shuqun Cheng, Xingsheng Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bin ZhouDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Zihui MaDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Lei WangDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Yue LuDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xi ChengDepartment of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Yabo JiangDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Xubiao WeiDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Chongde LuDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Shuqun ChengDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
Xingsheng LuDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.ORCID 0000-0002-8984-1409

Funding

Clinical Key Disease Diagnosis and Treatment Technology Project of Suzhou Municipal Health Commission LCZX202235Naval Medical University and Eastern Hepatobiliary Surgery Hospital 2022QN098/2022GZR007Shanghai Municipal Health Commission Health Industry Clinical Research Special 20244Y0165Shanghai Municipal Science and Technology Commission 22Y11908900
6 · The paper itself

Abstract

backgroundSintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT. PATIENTS AND

methodsThis retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).

resultsBaseline characteristics showed similar distributions between the two groups. SBRT + Sin + Bev group showed a significant increase in both median OS (18.9 vs 9.3 months, P < .001), median PFS (9.1 vs 4.7 months, P = .0015), and ORR (64.6% vs 26.3%, P = .031) compared to Sin + Bev group. TRAEs in SBRT + Sin + Bev group were mostly manageable and acceptable compared to Sin + Bev group. Multivariate analysis confirmed that SBRT + Sin + Bev was an independent prognostic factor for better OS (P < .001) and better PFS (P < .001).

conclusionSBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsPortal VeinRadiosurgeryVenous ThrombosisAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedBevacizumabsintilimabbevacizumabhepatocellular carcinomaportal vein tumor thrombusreal-world studysintilimabstereotactic body radiotherapy

Identifiers

PMID41495001
PMCPMC12854084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.